Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT07150845

Phase 2b Study of EVO756 in Adults With Atopic Dermatitis

This study will evaluate the efficacy and safety of different doses of EVO756 in adults with moderate to severe atopic dermatitis.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Conditions

Atoptic Dermatitis Congenital, Hereditary, and Neonatal Diseases and Abnormalities Dermatitis Dermatitis, Atopic Eczema Genetic Diseases, Inborn Hypersensitivity Hypersensitivity, Immediate Immune System Diseases Pathological Conditions, Signs and Symptoms Pruritus Signs and Symptoms Skin Diseases Skin Diseases, Eczematous Skin Diseases, Genetic Skin Manifestations Skin and Connective Tissue Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Pacific Clinical Research Network (PCRN) - Christchurch, Christchurch Central City, Christchurch, New Zealand

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Chronic AD that has been present for ≥6 months
  • Validated-Investigator's Global Assessment score of ≥3
  • EASI of ≥16
  • BSA of AD involvement of ≥10%

Exclusion criteria

  • Any clinically significant abnormality in laboratory evaluations, physical examinations, vital signs, or ECG at Screening
  • Use of certain medications
  • Presence of skin comorbidities or other condition(s) that may interfere with study assessments
  • Significant AD flare, in the opinion of the Investigator, within 4 weeks prior to study entry

Treatment and study plan

EVO756

Drug

Dose 1

Placebo Control

Drug

Placebo control

Primary outcomes

  1. Percentage change in Eczema Area and Severity Index (EASI) from Baseline

    Time frame: Week 12

Secondary outcomes

  1. Percentage change in EASI from Baseline

    Time frame: Weeks 2, 4, and 8

  2. Mean changes in EASI from Baseline

    Time frame: Week 2, 4, 8, and 12

  3. Proportion of subjects with EASI-50, EASI-75, and EASI-90 from Baseline

    Time frame: Weeks 2, 4, 8, and 12

  4. Mean and absolute changes in validated Investigator Global Assessment (vIGA) score from Baseline

    Time frame: Weeks 2, 4, 8, and 12

  5. Proportion of subjects achieving a vIGA score of 0,1 with at least a 2-point reduction from Baseline

    Time frame: Weeks 2, 4, 8, and 12

  6. Mean and percentage change from Baseline in the pruritus-NRS score

    Time frame: Weeks 2, 4, 8, and 12

  7. Proportion of subjects achieving a 4-pt reduction in the pruritus-NRS score from Baseline

    Time frame: Week 2, 4, 8, and 12

  8. Mean and percentage changes from Baseline in Body Surface Area (BSA) of affected area

    Time frame: Weeks 2, 4, 8, and 12

  9. Occurrence of treatment emergent adverse events (TEAE) and serious adverse events (SAE)

    Time frame: through Week 14

Sponsors and collaborators

Lead sponsor

Evommune, Inc.

Industry

Registry information

Official study title

A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy and Safety of EVO756 in Adults With Atopic Dermatitis

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Sep 2, 2025
Registry last updated
May 18, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.